Comprehensive care of the patient with idiopathic pulmonary fibrosis

@article{Lee2011ComprehensiveCO,
  title={Comprehensive care of the patient with idiopathic pulmonary fibrosis},
  author={Joyce S Lee and Sally McLaughlin and Harold R. Collard},
  journal={Current Opinion in Pulmonary Medicine},
  year={2011},
  volume={17},
  pages={348–354}
}
Purpose of review Recently, an expert committee endorsed by the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and the Latin American Thoracic Society published an evidence-based guideline on the management of idiopathic pulmonary fibrosis (IPF). In the current document, we summarize and supplement this recent expert document and propose a comprehensive approach to the care and management of patients with IPF. Recent findings We propose three pillars of… Expand
A comprehensive and practical approach to the management of idiopathic pulmonary fibrosis
TLDR
By incorporating this comprehensive approach to disease management, physicians can address most aspects of care for a patient with IPF to optimize survival and quality of life. Expand
Nonpharmacologic Therapy for Idiopathic Pulmonary Fibrosis
TLDR
The role of nonpharmacologic therapy in the care of patients with idiopathic pulmonary fibrosis is focused primarily on symptom management and falls in the realm of palliative care. Expand
Gaps in care of patients living with pulmonary fibrosis: a joint patient and expert statement on the results of a Europe-wide survey
TLDR
The aim of this joint expert and patient statement was to highlight the most pressing common unmet needs of patients with PF/IPF, putting forward recommendations to improve the quality of life and health outcomes throughout the patient journey. Expand
Guidelines of the Polish Respiratory Society for diagnosis and treatment of idiopathic pulmonary fibrosis.
TLDR
The experts suggest that surgical lung biopsy not be performed in patients with the probable usual interstitial pneumonia (UIP) pattern, with an appropriate clinical context and unanimous opinion of a multidisciplinary team. Expand
Management of Idiopathic Pulmonary Fibrosis in the Elderly Patient: Addressing Key Questions.
TLDR
The monitoring and treatment of patients with IPF, especially elderly patients with comorbid medical conditions, require consideration of adverse side effects, the avoidance of potential drug-drug interactions, treatment ofComorbidities, and the timely implementation of supportive and palliative measures. Expand
Role of support measures and palliative care
Purpose of review The care of patients with idiopathic pulmonary fibrosis is challenging at a time when there are no medications with proven efficacy in extending patient survival or quality of life.Expand
Pulmonary fibrosis, part II: state-of-the-art patient management
  • K. Meyer
  • Medicine
  • Expert review of respiratory medicine
  • 2017
TLDR
Whether anti-fibrotic agents can be effective therapies for other forms of pulmonary fibrosis, which often have radiologic and histopathologic manifestations that mimic IPF, is being evaluated in a number of RCTs. Expand
Palliative Care in Diffuse Interstitial Lung Disease: Results of a Spanish Survey
TLDR
Despite the well-known need for palliative care in patients with ILD and the notable interest of the survey participants in this subject, there are clear formative and organizational gaps that should be addressed to improve care in this area in ILD patients in Spain. Expand
Patient-centred management in idiopathic pulmonary fibrosis: similar themes in three communication models
TLDR
Three communication models will be described: 1) the patient-centred care model (for oncology); 2) the three pillars of care models (for IPF); and 3) the Brompton model of care (for interstitial lung disease). Expand
The care needs of patients with idiopathic pulmonary fibrosis and their carers (CaNoPy): results of a qualitative study
TLDR
In depth analysis of the experiences of patients and carers offers guidance for refining IPF clinical pathways in line with National Institute for Health and Care Excellence (NICE) guidance. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 53 REFERENCES
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.
TLDR
This document represents the current state of knowledge regarding idiopathic pulmonary fibrosis, and contains sections on definition and epidemiology, risk factors, diagnosis, natural history, staging and prognosis, treatment, and monitoring disease course. Expand
Patients' perspectives on how idiopathic pulmonary fibrosis affects the quality of their lives
TLDR
Collecting patients' perspectives and developing an organized inventory of the relevant effects of IPF on patients' lives provides valuable information for improving the understanding of the impact of this disease on patients and their loved ones. Expand
Dyspnea in idiopathic pulmonary fibrosis: a systematic review.
TLDR
Sildenafil and pulmonary rehabilitation should be considered as potential therapies for dyspnea in selected patients with IPF and supplemental oxygen and opioids may be additional potential therapies; however, the evidence supporting their use is weak. Expand
Corticosteroids in idiopathic pulmonary fibrosis
TLDR
A rationale for stratifying therapy based on host, demographic, and clinical factors that influence prognosis as well as risk for corticosteroid complications is presented. Expand
American College of Chest Physicians consensus statement on the management of dyspnea in patients with advanced lung or heart disease.
TLDR
Patients with advanced lung or heart disease should be asked to rate the intensity of their breathlessness as part of a comprehensive care plan, opioids should be dosed and titrated for relief of dyspnea in the individual patient, and both the patient and clinician should reassess whether specific treatments are serving the goal of palliating Dyspnea without causing adverse effects. Expand
Anticoagulant therapy for idiopathic pulmonary fibrosis.
TLDR
The data suggested that plasma d-dimer levels are associated with mortality in patients with an acute exacerbation of IPF, and that anticoagulant therapy has a beneficial effect on survival in Patients with IPF. Expand
Chronic cough due to chronic interstitial pulmonary diseases: ACCP evidence-based clinical practice guidelines.
TLDR
In patients with cough, chronic interstitial pulmonary disease should be considered as a primary cause only after more common causes, such as upper airway cough syndrome and gastroesophageal reflux, have been excluded. Expand
Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.
TLDR
The data suggest that combined corticosteroid and cyclophosphamide therapy has no impact on survival in patients with IPF, and supports the evolving concept that chronic inflammation plays a minimal role in the progression of IPF. Expand
Outcome of patients with idiopathic pulmonary fibrosis (IPF) ventilated in intensive care unit.
TLDR
Patients and their families should be informed about the prognosis, outcome and overall outlook before making decision about ventilation and organ support, and institutional and professional guidelines should be used to help in making these difficult decisions. Expand
Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis.
TLDR
Lung transplantation is effective in improving the survival of selected patients affected by idiopathic pulmonary fibrosis, and multivariable analysis showed that lung transplantation reduced the risk of death by 75% after adjustment on potential confounding variables. Expand
...
1
2
3
4
5
...